{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.9","upperLimit":"128.7","value":"112.1"}]}],"title":"Overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.8","upperLimit":"69.03","value":"12.3"}]}],"title":"Progression-free survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a \\>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \\< 5% plasma cells.","dispersionType":"Full Range","groups":[{"description":"therapeutic autologous lymphocytes","id":"OG000","title":"MILs in Patients Undergoing an Autologous Peripheral SCT"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 129 months","title":"Survival","type":"SECONDARY","unitOfMeasure":"months"}